Loading clinical trials...
Loading clinical trials...
Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma
Conditions
Interventions
Docetaxel
cetuximab
+1 more
Locations
47
United States
Birmingham Hematology and Oncology
Birmingham, Alabama, United States
Hematology Oncology Associates
Phoenix, Arizona, United States
Rocky Mountain Cancer Center - Midtown
Denver, Colorado, United States
Florida Cancer Institute
New Port Richey, Florida, United States
Ocala Oncology Center
Ocala, Florida, United States
Hematology Oncology Associates of Illinois
Chicago, Illinois, United States
Start Date
July 1, 2007
Primary Completion Date
April 1, 2012
Completion Date
April 1, 2012
Last Updated
November 28, 2016
Lead Sponsor
US Oncology Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions